Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148465 | 0.82 | TRPA1 (0.33) | ACHETSHRSMN1; SMN2 | |
| O-Tolylamine SCHEMBL578081 | 0.82 | ACHE (0.38) | ACHETSHRHTTKDM4C | |
| O-Xylene SCHEMBL30386408 | 0.80 | TSHR (0.48) | ACHECYP1A2CYP2A6TSHRCA1 | |
| O-Xylene SCHEMBL30509215 | 0.80 | TSHR (0.48) | ACHECYP1A2CYP2A6TSHRCA1 | |
| SCHEMBL17817761 | 0.79 | RAPGEF4 (0.33) | — | |
| SCHEMBL30746773 | 0.79 | CYP2A6 (0.37) | ACHECYP1A2CYP2A6TSHRCA1 | |
| SCHEMBL30468920 | 0.79 | ACHE (0.34) | ACHECYP1A2CYP2A6TSHRCA1 | |
| SCHEMBL28215053 | 0.79 | ACHE (0.34) | ACHECYP1A2CYP2A6TSHRCA1 | |
| SCHEMBL399537 | 0.78 | ACHE (0.33) | ACHECYP1A2CYP2A6CA1CA2 | |
| SCHEMBL218368 | 0.78 | ACHE (0.33) | ACHECYP1A2CYP2A6CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1034196-B1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | PROMERUS LLC (US) | 2005-01-12 | — | — | EP | claimed |
| US-20030023013-A1 | Catalyst and methods for polymerizing cycloolefins | THE B.F.GOODRICH COMPANY | 2003-01-30 | — | — | US | claimed |
| US-6455650-B1 | CONTACTING POLYCYCLOOLEFIN MONOMER WITH A HIGH ACTIVITY GROUP 10 TRANSITION METAL CATALYST COMPLEX TO OBTAIN POLYMER PRODUCT | THE B.F. GOODRICH COMPANY | 2002-09-24 | — | — | US | claimed |
| US-20020052454-A1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | SUMITOMO BAKELITE CO., LTD. (JP) | 2002-05-02 | — | — | US | claimed |
| EP-1034196-A1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | THE B.F. GOODRICH COMPANY (US) | 2000-09-13 | — | — | EP | claimed |
| WO-2000020472-A1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | THE B.F. GOODRICH COMPANY (US) | 2000-04-13 | — | — | WO | claimed |
| EP-4612126-A1 | COMPOSITIONS INCLUDING A MIXTURE OF ISOMERS OF ITACONIMIDE NORBORNENE AND CITRACONIMIDE NORBORNENE | 3M Innovative Properties Company (US) | 2025-09-10 | — | — | EP | disclosed |
| CN-120152955-A | Compositions comprising isomer mixtures of itaconimide norbornene and citraconimide norbornene | 3M创新有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20240279251-A1 | Monomer, Polymerizable Composition, and Polymers Derived Therefrom | 3M INNOVATIVE PROPERTIES COMPANY | 2024-08-22 | — | — | US | disclosed |
| WO-2024095078-A1 | COMPOSITIONS INCLUDING A MIXTURE OF ISOMERS OF ITACONIMIDE NORBORNENE AND CITRACONIMIDE NORBORNENE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240002586-A1 | CURABLE COMPOSITIONS, COMPOSITE FOAM, METHOD OF MAKING THE SAME, AND ARTICLE INCLUDING THE SAME | 3M INNOVATIVE PROPERTIES COMPANY | 2024-01-04 | — | — | US | disclosed |
| CN-117295752-A | Monomers, polymerizable compositions, and polymers derived therefrom | 3M创新有限公司 | 2023-12-26 | — | — | CN | disclosed |
| WO-2022238774-A1 | MONOMER, POLYMERIZABLE COMPOSITION, AND POLYMERS DERIVED THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2022-11-17 | — | — | WO | disclosed |
| US-20020103317-A1 | Polymeric compositions for forming optical waveguides; optical waveguides formed therefrom; and methods for making same | SUMITOMO BAKELITE CO., LTD. (JP) | 2002-08-01 | — | — | US | disclosed |
| US-20020064896-A1 | Optical waveguides and methods for making the same | 3M INNOVATIVE PROPERTIES COMPANY | 2002-05-30 | — | — | US | disclosed |
| US-20020052454-A1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | SUMITOMO BAKELITE CO., LTD. (JP) | 2002-05-02 | — | — | US | disclosed |
| WO-2002010810-A2 | OPTICAL WAVEGUIDES AND METHODS FOR MAKING THE SAME | GOODRICH CORPORATION (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2002010231-A2 | POLYMERIC COMPOSITIONS FOR FORMING OPTICAL WAVEGUIDES; OPTICAL WAVEGUIDES FORMED THEREFROM; AND METHODS FOR MAKING SAME | GOODRICH CORPORATION (US) | 2002-02-07 | — | — | WO | disclosed |
| EP-1034196-A1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | THE B.F. GOODRICH COMPANY (US) | 2000-09-13 | — | — | EP | disclosed |
| WO-2000020472-A1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | THE B.F. GOODRICH COMPANY (US) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279251-A1 | Monomer, Polymerizable Composition, and Polymers Derived Therefrom | PBRM1, CARM1, WASF2 | ACHE 4772/4885CYP1A2 2802/4885CYP2A6 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.